CN119522092A - 用于核酸递送的基于多价分子的脂质纳米颗粒 - Google Patents
用于核酸递送的基于多价分子的脂质纳米颗粒 Download PDFInfo
- Publication number
- CN119522092A CN119522092A CN202380044712.0A CN202380044712A CN119522092A CN 119522092 A CN119522092 A CN 119522092A CN 202380044712 A CN202380044712 A CN 202380044712A CN 119522092 A CN119522092 A CN 119522092A
- Authority
- CN
- China
- Prior art keywords
- apo
- apolipoprotein
- multivalent
- core
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/028—Polyamidoamines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22177313.8 | 2022-06-03 | ||
| EP22177313 | 2022-06-03 | ||
| PCT/EP2023/064963 WO2023233042A1 (en) | 2022-06-03 | 2023-06-05 | Polyvalent molecule based lipid nanoparticles for nucleic acid delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119522092A true CN119522092A (zh) | 2025-02-25 |
Family
ID=81940594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380044712.0A Pending CN119522092A (zh) | 2022-06-03 | 2023-06-05 | 用于核酸递送的基于多价分子的脂质纳米颗粒 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250325491A1 (enExample) |
| EP (1) | EP4531818A1 (enExample) |
| JP (1) | JP2025518282A (enExample) |
| KR (1) | KR20250031158A (enExample) |
| CN (1) | CN119522092A (enExample) |
| AU (1) | AU2023278446A1 (enExample) |
| CA (1) | CA3258109A1 (enExample) |
| IL (1) | IL317412A (enExample) |
| MX (1) | MX2024014961A (enExample) |
| WO (1) | WO2023233042A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119431176A (zh) * | 2024-11-05 | 2025-02-14 | 汉信生物科技(苏州)有限公司 | 一种可电离阳离子脂质及其制备方法和应用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024125469A1 (en) * | 2022-12-12 | 2024-06-20 | Starna Therapeutics | Novel compounds and use thereof for targeted delivery |
| WO2025073054A1 (en) | 2023-10-05 | 2025-04-10 | Nanovation Therapeutics Inc. | Method of delivery of dna or rna cargo using unshielded lipid nanoparticles |
| WO2025245869A1 (zh) * | 2024-05-31 | 2025-12-04 | 清华大学 | 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4995423B2 (ja) * | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2017048789A1 (en) | 2015-09-14 | 2017-03-23 | The Board Of Regents Of The University Of Texas System | Lipocationic dendrimers and uses thereof |
| CN109414408B (zh) * | 2016-05-16 | 2022-03-29 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
| EP3713548A4 (en) | 2017-11-21 | 2021-06-23 | Icahn School of Medicine at Mount Sinai | Promoting trained immunity with therapeutic nanobiologic compositions |
| CN113616602B (zh) * | 2021-08-31 | 2022-05-10 | 中国药科大学 | 一种重组高密度脂蛋白-聚酰胺-胺纳米复合物、制法及应用 |
-
2023
- 2023-06-05 CA CA3258109A patent/CA3258109A1/en active Pending
- 2023-06-05 KR KR1020247043050A patent/KR20250031158A/ko active Pending
- 2023-06-05 JP JP2024570980A patent/JP2025518282A/ja active Pending
- 2023-06-05 US US18/870,116 patent/US20250325491A1/en active Pending
- 2023-06-05 AU AU2023278446A patent/AU2023278446A1/en active Pending
- 2023-06-05 WO PCT/EP2023/064963 patent/WO2023233042A1/en not_active Ceased
- 2023-06-05 CN CN202380044712.0A patent/CN119522092A/zh active Pending
- 2023-06-05 EP EP23731182.4A patent/EP4531818A1/en active Pending
- 2023-06-05 IL IL317412A patent/IL317412A/en unknown
-
2024
- 2024-12-02 MX MX2024014961A patent/MX2024014961A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119431176A (zh) * | 2024-11-05 | 2025-02-14 | 汉信生物科技(苏州)有限公司 | 一种可电离阳离子脂质及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024014961A (es) | 2025-01-09 |
| US20250325491A1 (en) | 2025-10-23 |
| AU2023278446A1 (en) | 2024-10-31 |
| JP2025518282A (ja) | 2025-06-12 |
| EP4531818A1 (en) | 2025-04-09 |
| IL317412A (en) | 2025-02-01 |
| KR20250031158A (ko) | 2025-03-06 |
| WO2023233042A1 (en) | 2023-12-07 |
| CA3258109A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7367137B2 (ja) | 薬剤の細胞内送達のための化合物および組成物 | |
| CN119522092A (zh) | 用于核酸递送的基于多价分子的脂质纳米颗粒 | |
| US10626393B2 (en) | Delivering CRISPR therapeutics with lipid nanoparticles | |
| AU2022219902A1 (en) | Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same | |
| US20180245074A1 (en) | Treating hepatitis b virus infection using crispr | |
| ES2561812T3 (es) | Composición para inhibir la expresión de un gen diana | |
| CN105555757A (zh) | 用于递送信使rna的组合物和方法 | |
| CN101060849A (zh) | 作为有效的siRNA载体的高分支HK肽 | |
| EP4334455A1 (en) | Lipid compositions comprising peptide-lipid conjugates | |
| CN117545467A (zh) | 含有核酸的纳米颗粒 | |
| AU2021297248A1 (en) | LNP compositions comprising mRNA therapeutics with extended half-life | |
| FR2766706A1 (fr) | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation | |
| CN103608354B (zh) | 含有pH-响应肽的纳米颗粒 | |
| US20240207187A1 (en) | Dendritic architectures as nonviral vectors in gene delivery | |
| CN118201639A (zh) | 肽-脂质缀合物 | |
| CN104755490B (zh) | 弱酸性pH响应性肽和含有其的脂质体 | |
| TW202315601A (zh) | ApoE胜肽之使用方法 | |
| CN117460537A (zh) | 核酸递送 | |
| KR102944341B1 (ko) | 핵산 전달용 신규 이온화 지질 | |
| WO2024110492A9 (en) | Novel carriers for nucleic acid and/or protein delivery | |
| HK40078722A (en) | Compounds and compositions for intracellular delivery of agents | |
| HK1193112B (en) | Nanoparticles containing ph-responsive peptide | |
| HK1193112A (en) | Nanoparticles containing ph-responsive peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |